ATE296117T1 - Verwendung von adenoviralen vektoren, die pdgf oder vegf exprimieren, zur heilung von gewebsdefekten und zur induzierung der hypervaskulität in säugergeweben - Google Patents

Verwendung von adenoviralen vektoren, die pdgf oder vegf exprimieren, zur heilung von gewebsdefekten und zur induzierung der hypervaskulität in säugergeweben

Info

Publication number
ATE296117T1
ATE296117T1 AT98909027T AT98909027T ATE296117T1 AT E296117 T1 ATE296117 T1 AT E296117T1 AT 98909027 T AT98909027 T AT 98909027T AT 98909027 T AT98909027 T AT 98909027T AT E296117 T1 ATE296117 T1 AT E296117T1
Authority
AT
Austria
Prior art keywords
growth factor
tissue
vegf
hypervasculism
induce
Prior art date
Application number
AT98909027T
Other languages
English (en)
Inventor
Meenhard Herlyn
Mark Nesbit
Kapaettu Satyamoorthy
Original Assignee
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst filed Critical Wistar Inst
Application granted granted Critical
Publication of ATE296117T1 publication Critical patent/ATE296117T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98909027T 1997-03-07 1998-03-06 Verwendung von adenoviralen vektoren, die pdgf oder vegf exprimieren, zur heilung von gewebsdefekten und zur induzierung der hypervaskulität in säugergeweben ATE296117T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4004297P 1997-03-07 1997-03-07
PCT/US1998/004487 WO1998039035A1 (en) 1997-03-07 1998-03-06 Method and compositions for healing tissue defects and inducing hypervascularity in mammalian tissue

Publications (1)

Publication Number Publication Date
ATE296117T1 true ATE296117T1 (de) 2005-06-15

Family

ID=21908774

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98909027T ATE296117T1 (de) 1997-03-07 1998-03-06 Verwendung von adenoviralen vektoren, die pdgf oder vegf exprimieren, zur heilung von gewebsdefekten und zur induzierung der hypervaskulität in säugergeweben

Country Status (6)

Country Link
US (1) US6486133B1 (de)
EP (1) EP1017421B1 (de)
AT (1) ATE296117T1 (de)
AU (1) AU6691098A (de)
DE (1) DE69830320T2 (de)
WO (1) WO1998039035A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0751992T3 (da) 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
KR100470180B1 (ko) 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1374889A1 (de) * 1999-06-25 2004-01-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Verfahren zur Induktion von Angiogenese mittels Mikro-Organen
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
WO2001023003A1 (en) * 1999-09-28 2001-04-05 Cornell Research Foundation, Inc. Tissue flap angiogenesis
US6830920B2 (en) * 2000-03-08 2004-12-14 University Of Iowa Research Foundation Rapid generation of recombinant adenoviral vectors
EP1157999A1 (de) * 2000-05-24 2001-11-28 Introgene B.V. Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
MXPA02003434A (es) 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
CA2421864A1 (en) * 2000-09-20 2002-03-28 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
US7235233B2 (en) * 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
AU2002211561A1 (en) * 2000-10-11 2002-04-22 The Wistar Institute Regulation of human skin healing
EP1330252A4 (de) * 2000-11-01 2007-12-26 Ludwig Inst Cancer Res In-vivo-stimulierung der angiogenen aktivität
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
MXPA03009408A (es) 2001-04-13 2004-01-29 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
US7217570B2 (en) * 2001-08-23 2007-05-15 The Wistar Institute Of Anatomy And Biology Organotypic intestinal culture and methods of use thereof
US7468242B2 (en) 2001-11-05 2008-12-23 Medgenics, Inc. Dermal micro organs, methods and apparatuses for producing and using the same
US8501396B2 (en) 2001-11-05 2013-08-06 Medgenics Medical Israel Ltd. Dermal micro-organs, methods and apparatuses for producing and using the same
ATE447037T1 (de) * 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
EP1534345A4 (de) * 2002-07-12 2012-03-21 Yissum Res Dev Co Verfahren und vorrichtung zur einleitung biologischer prozesse durch mikroorgane
EP2377404A1 (de) 2003-05-01 2011-10-19 Medgenics, Inc. Dermisches Mikroorgan, das ein Explantat einer lebenden Leber ist
US7326571B2 (en) 2003-07-17 2008-02-05 Boston Scientific Scimed, Inc. Decellularized bone marrow extracellular matrix
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
CN101610793B (zh) 2006-09-14 2012-10-24 迈德詹尼克斯医疗以色列有限公司 长效药物制剂
US9127084B2 (en) 2006-09-14 2015-09-08 Medgenics Medical Israel Ltd. Long lasting drug formulations
US20130184348A1 (en) 2010-09-17 2013-07-18 Shiseido Company, Ltd. Skin activation by acceleration of pdgf-bb activity
CN113474457A (zh) * 2018-12-24 2021-10-01 细胞基因治疗有限公司 基因疗法dna载体及其应用
WO2021092251A1 (en) 2019-11-05 2021-05-14 Apeel Technology, Inc. Prediction of infection in plant products

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073492A (en) 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5661132A (en) * 1989-12-14 1997-08-26 Auragen, Inc. Wound healing
DE69132040T2 (de) 1990-09-21 2000-11-02 Merck & Co., Inc. Wachstumsfaktor II für vaskuläre Endothelzellen
EP0506477B1 (de) 1991-03-28 1999-06-23 Merck & Co. Inc. Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors
EP0550296A3 (en) 1991-11-28 1993-12-29 Terumo Corp Vascular endothelial cells growth factor
WO1993013807A1 (en) * 1992-01-10 1993-07-22 Georgetown University A method of administering genetically engineered endothelial cells to sites of angiogenesis for effecting genetic therapy
US5977095A (en) * 1993-03-09 1999-11-02 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome
US5641756A (en) 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
US6410322B1 (en) 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5731294A (en) 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
US5480975A (en) 1994-02-08 1996-01-02 Brigham And Women's Hospital Induction of vascular endothelial growth factor (VEGF) by transition metals
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
DK0751992T3 (da) * 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
GB9410533D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
CA2188575A1 (en) * 1995-02-28 1996-09-06 H. Kirk Hammond Gene transfer-mediated angiogenesis therapy
US5928939A (en) 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
EP0857209A1 (de) * 1995-06-05 1998-08-12 Human Genome Sciences, Inc. Fibroblastenwachstumsfaktor 13
US6162796A (en) 1995-09-27 2000-12-19 The Rockefeller University Method for transferring genes to the heart using AAV vectors
EP1486565B1 (de) 1995-10-11 2007-11-21 Novartis Vaccines and Diagnostics, Inc. Kombinierung von PDGF, KGF, IGF und IGFBP für Wundheilung
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US5869037A (en) * 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
US5980887A (en) 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
WO1998038729A1 (en) 1997-02-28 1998-09-03 Clifton Gerard Anderson Portable power generator
AU3072099A (en) * 1998-03-13 1999-09-27 Human Genome Sciences, Inc. Vascular endothelial growth factor 2

Also Published As

Publication number Publication date
EP1017421A1 (de) 2000-07-12
EP1017421B1 (de) 2005-05-25
EP1017421A4 (de) 2001-06-27
WO1998039035A1 (en) 1998-09-11
US6486133B1 (en) 2002-11-26
DE69830320D1 (de) 2005-06-30
DE69830320T2 (de) 2006-02-02
AU6691098A (en) 1998-09-22

Similar Documents

Publication Publication Date Title
ATE296117T1 (de) Verwendung von adenoviralen vektoren, die pdgf oder vegf exprimieren, zur heilung von gewebsdefekten und zur induzierung der hypervaskulität in säugergeweben
Zemlyak et al. LOP59: absorbable glycolic acid/trimethylene carbonate synthetic mesh demonstrates superior in-growth and collagen deposition
Thamm et al. LOP26: Autologous Fat Grafting Improves Wound Healing
de Weerd et al. LOP01: Preoperative perforator mapping with dynamic infrared thermography in breast reconstruction with a DIEP flaps
Clemens et al. LOP04: Rapid Recovery Protocol in Complex Head & Neck Free Tissue Transfer
Maman et al. LOP49: immediate single-stage breast implant reconstruction with absorbable mesh
Lago et al. LOP33: A Complex ECM 3D Scaffold with Vascular Channels by Decellularization of Human and Rat Omentum
Keck et al. LOP41: First Experiences with a New Surgical Approach for Patients Suffering from Deep Burns: Single Step Reconstruction of Epidermis, Dermis and Subcutis by Use of Split Thickness Skin Grafting, Dermal Replacement and Lipo-Transfer
Kraus et al. LOP10: Optimization of Flexor Tendon Tissue Engineering: Human Adipoderived Stem Cell-Tenocyte Co-Cultures for Seeding of an Acellularized Tendon Scaffolds
Kapaj et al. LOP46: Composite Tissue Xenopreservation: A New Living Tissue Bank
Kuhbier et al. LOP35: Chemical and Immunological Testing of Spider Silk as a Biopolymer
Schonauer et al. LOP30: Elective Localization of the Dermatofibrosarcoma Protuberans in the Left Chest
Broelsch et al. LOP15: The Effect of Type and Degree of Pressure on Fat Grafting
Nikkhah et al. LOP19: Planning Surgical Reconstruction in Treacher-Collins Syndrome Using Geometric Morphometrics
Fourman et al. LOP47: Acute Administration of Empty Viral Vector Causes Substantial Improvement in Dorsal Skin Flap Survival in Rat Models
Haug et al. LOP36: The Coimplantation of Human Adipose Derived Stem Cells with Endothelial Progenitor Cells for Adipose Tissue Engineering In Vivo
Bouguila et al. LOP38: Rhinoplasty in the Burned Nose
Teo et al. LOP31: Radiation Induced Sarcoma
van Koot et al. LOP34: Fabrication of Biocompatible Bio-degradable Artificial Tissue Constructs via Sacrificial Nonionic Triblock Copolymer Networks
Bader et al. LOP21: Midfacial Anthropometric Changes after Surgical Assisted Rapid Palatal Expansion
Scherer et al. LOP54: Micro-Topographical Control of Fibroblast Adhesion and Function on Silicone Implants: A New Strategy to Reduce Capsular Contraction
Verdonck et al. LOP25: Angiogenic Factors Placental Growth Factor (PlGF) and Vascular Endothelial Growth Factor (VEGF) are in Part Responsible for the Beneficial Effects of Human Blood Outgrowth Endothelial Cells (hBOECs) and Dermal Fibroblast Sheets (hDFS) on Wound Healing
Zegrea et al. LOP58: A New Collagen Conduit for the Regeneration of the Peripheral Nerves Using Tissue Engineering-Final Result
Qader LOP39: Sub Eschar Infilteration of Epiniphrine in Early Excision and Skin Grafting to Decrease Blood Loss in Burn Surgery
Phillips et al. LOP53: Antibiotic Use and Infection in Breast Reconstruction with Acellular Dermal Matrix: A Review of the Literature

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties